9966 — Alphamab Oncology Share Price
Last trade - 00:00- HK$4.59bn
- HK$3.34bn
- CNY218.77m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.55 | ||
| Price to Tang. Book | 2.55 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 16.21 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -11.4% | ||
| Return on Equity | -12.41% | ||
| Operating Margin | -80.06% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | n/a | n/a | 146.02 | 166.84 | 218.77 | 336.53 | 430.54 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Alphamab Oncology is an investment holding company primarily engaged in the biopharmaceutical business. The Company is a full-industry chain enterprise specializing in research, development, manufacture, and commercialization of innovative tumor immunobiology macromolecular targeted drugs. The Company has bio-innovation drug development technology platform, including protein engineering platform, multi-functional antibody development platform and antibody screening platform. The Company operates its businesses in both domestic and overseas markets.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- March 28th, 2018
- Public Since
- December 12th, 2019
- No. of Employees
- 429
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 963,901,807
- Address
- No. 175, Suzhou, 215125
- Web
- https://www.alphamabonc.com/en/
- Phone
- +86 51262850800
- Auditors
- Deloitte Touche Tohmatsu
Upcoming Events for 9966
Similar to 9966
Abbisko Cayman
Stock Exchange of Hong Kong Limited
Akeso
Stock Exchange of Hong Kong Limited
Antengene
Stock Exchange of Hong Kong Limited
Ascentage Pharma International
Stock Exchange of Hong Kong Limited
Beigene
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 19:11 UTC, shares in Alphamab Oncology are trading at HK$4.76. This share price information is delayed by 15 minutes.
Shares in Alphamab Oncology last closed at HK$4.76 and the price had moved by -42.23% over the past 365 days. In terms of relative price strength the Alphamab Oncology share price has underperformed the FTSE Developed Asia Pacific Index by -51.73% over the past year.
The overall consensus recommendation for Alphamab Oncology is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreAlphamab Oncology does not currently pay a dividend.
Alphamab Oncology does not currently pay a dividend.
Alphamab Oncology does not currently pay a dividend.
To buy shares in Alphamab Oncology you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$4.76, shares in Alphamab Oncology had a market capitalisation of HK$4.59bn.
Here are the trading details for Alphamab Oncology:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 9966
Based on an overall assessment of its quality, value and momentum Alphamab Oncology is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Alphamab Oncology is HK$5.08. That is 6.81% above the last closing price of HK$4.76.
Analysts covering Alphamab Oncology currently have a consensus Earnings Per Share (EPS) forecast of -CNY0.22 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Alphamab Oncology. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +9.29%.
As of the last closing price of HK$4.76, shares in Alphamab Oncology were trading +20.56% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Alphamab Oncology PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$4.76.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Alphamab Oncology's directors